Multiple Myeloma
June 2018 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Multiple Myeloma abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Multiple Myeloma. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Multiple Myeloma. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Multiple Myeloma every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:Going the distance: Are we losing patients along the multiple myeloma treatment pathway?
Authors:Terpos E, Suzan F, Goldschmidt H
Institution:Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. Electronic address: Center for Tumor Diseases (NCT), Heidelberg, Germany.
Journal:Crit Rev Oncol Hematol. 2018 Jun;126:19-23. doi: 10.1016/j.critrevonc.2018.03.021. Epub 2018 Mar 29.

2:Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.
Authors:Mushtaq A, Kapoor V, Latif A, Iftikhar A, Zahid U, McBride A, Abraham I, Riaz IB, Anwer F
Institution:Department of Medicine, Hematology and Oncology, University of Arizona, Tucson, AZ, United States. AZ, United States. AZ, United States. AZ, United States. AZ, United States; College of Public Health, University of Arizona, Tucson, AZ, United States. 85721, United States. United States. AZ, United States. Electronic address:
Journal:Crit Rev Oncol Hematol. 2018 May;125:1-11. doi: 10.1016/j.critrevonc.2018.02.008. Epub 2018 Mar 2.

3:Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies.
Authors:Chen M, Zhao Y, Xu C, Wang X, Zhang X, Mao B
Institution:Department of Pharmacy, Yangtze University Affiliated Hospital Jingzhou, Hangkong Street 8, Jingzhou, Hubei, 434000, China. Jinlong Street 8, Jingzhou, Hubei, 434000, China. Street 8, Jingzhou, Hubei, 434000, China. Street 8, Jingzhou, Hubei, 434000, China. Street 8, Jingzhou, Hubei, 434000, China. Jingzhou, Hangkong Street 8, Jingzhou, Hubei, 434000, China.
Journal:Ann Hematol. 2018 Jun;97(6):925-944. doi: 10.1007/s00277-018-3284-y. Epub 2018 Mar 2.

4:Proteasome inhibitors for the treatment of multiple myeloma.
Authors:Scalzulli E, Grammatico S, Vozella F, Petrucci MT
Institution:a Hematology, Department of Cellular Biotechnologies and Hematology , "Sapienza" University , Rome , Italy. University , Rome , Italy. University , Rome , Italy. University , Rome , Italy.
Journal:Expert Opin Pharmacother. 2018 Mar;19(4):375-386. doi: 10.1080/14656566.2018.1441287. Epub 2018 Feb 26.

5:Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Authors:Mateos MV, Goldschmidt H, San-Miguel J, Mikhael J, DeCosta L, Zhou L, Obreja M, Blaedel J, Szabo Z, Leleu X
Institution:University Hospital Salamanca, Salamanca, Spain. Germany.
Journal:Hematol Oncol. 2018 Apr;36(2):463-470. doi: 10.1002/hon.2499. Epub 2018 Feb 15.

6:Immunopathogenesis and immunotherapy of multiple myeloma.
Authors:Tamura H
Institution:Department of Hematology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Journal:Int J Hematol. 2018 Mar;107(3):278-285. doi: 10.1007/s12185-018-2405-7. Epub 2018 Jan 24.

7:Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft.
Authors:Gossi U, Jeker B, Mansouri Taleghani B, Bacher U, Novak U, Betticher D, Egger T, Zander T, Pabst T
Institution:Department of Medical Oncology, Inselspital, University Hospital of Bern, Bern, Switzerland. Switzerland. Switzerland. Switzerland. Switzerland.
Journal:Hematol Oncol. 2018 Apr;36(2):436-444. doi: 10.1002/hon.2490. Epub 2018 Jan 24.

8:A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.
Authors:Cook G, Zweegman S, Mateos MV, Suzan F, Moreau P
Institution:St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, UK. Electronic address:
Journal:Crit Rev Oncol Hematol. 2018 Jan;121:74-89. doi: 10.1016/j.critrevonc.2017.11.016. Epub 2017 Dec 5.

9:Triplet vs. doublet drug regimens for managing multiple myeloma.
Authors:Offidani M, Corvatta L, Gentili S
Institution:a Clinica di Ematologia , Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona , Ancona , Italy. Italy. Italy.
Journal:Expert Opin Pharmacother. 2018 Feb;19(2):137-149. doi: 10.1080/14656566.2017.1418856. Epub 2017 Dec 21.

10:Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Authors:Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B
Institution:Center for Evidence Based Medicine and Health Outcomes Research, University of South Florida, Tampa, Florida, USA.
Journal:Cochrane Database Syst Rev. 2017 Dec 18;12:CD003188. doi: 10.1002/14651858.CD003188.pub4.

11:Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Authors:Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J
Institution:From University Hospital of Salamanca-Instituto de Investigacion Biomedica de Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra, Centro de Investigacion Biomedica en Red de Cancer, Pamplona (J.S.-M.) - both in Spain; National and Kapodistrian University of Athens, Athens (M.A.D.); the Institute of Hematology, Department of Experimental, Diagnostic, and Specialty Medicine, University of Bologna, Bologna (M. Cavo), and Azienda Ospedaliera 'Santa Maria,' Terni (A.M.L.) - both in Italy; Japanese Red Cross Medical Center, Department of Hematology, Tokyo (K.S.); University of Chicago Medical Center, Chicago (A.J.); Wurzburg University Medical Center, Wurzburg, Germany (S.K.); Universite Catholique de Louvain (UCL), Centre Hospitalier Universitaire UCL Namur, Yvoir (C.D.), and Janssen Research and Development, Beerse (W.D.) - both in Belgium; Champalimaud Center for the Unknown, Lisbon, Portugal (P.L.); Semmelweis Egyetem, Budapest, Hungary (Z.N.); Dnepropetrovsk City Clinical Hospital #4, Dnepropetrovsk, Ukraine (P.K.); University Hospital Brno, Brno, Czech Republic (L.P.); University Hospitals Birmingham NHS Foundation Trust, Birmingham (M. Cook), and Leicester Royal Infirmary-Haematology, Leicester (M.G.) - both in the United Kingdom; the Department of Cancer Prevention, School of Public Health, Silesian Medical University, Katowice, Poland (S.G.); Clinica de Tratamento E, Cuiaba, Brazil (A.C.); Andrew Love Cancer Centre, Geelong, VIC, Australia (P.C.); Clinic of Professional Pathology, Saratov, Russia (T.S.); the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); LTD 'Medinvent' Institute of Health, Tbilisi, Georgia (G.I.); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); Janssen Research and Development, Spring House, PA (C.C., R.C., W.C., M.Q.); and Janssen Research and Development, Raritan, NJ (J.W., H.N.).
Journal:N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12.

12:The proteasome and proteasome inhibitors in multiple myeloma.
Authors:Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG
Institution:Dana-Farber Cancer Institute, 44 Binney Street, Dana 1B02, Boston, MA, 02115, USA. USA. USA. USA. USA. USA.
Journal:Cancer Metastasis Rev. 2017 Dec;36(4):561-584. doi: 10.1007/s10555-017-9707-8.

13:Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
Authors:Richardson PG, Holstein SA, Schlossman RL, Anderson KC, Attal M, McCarthy PL
Institution:a Dana-Farber Cancer Institute , Harvard Medical School , Boston , MA , USA. , NE , USA. Toulouse-Oncopole , Toulouse , France. NY , USA.
Journal:Expert Opin Pharmacother. 2017 Dec;18(18):1975-1985. doi: 10.1080/14656566.2017.1409207. Epub 2017 Dec 1.

14:Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Authors:Cohen A, Spektor TM, Stampleman L, Bessudo A, Rosen PJ, Klein LM, Woliver T, Flam M, Eshaghian S, Nassir Y, Maluso T, Swift RA, Vescio R, Berenson JR
Institution:Oncotherapeutics, West Hollywood, CA, USA.
Journal:Br J Haematol. 2018 Jan;180(1):60-70. doi: 10.1111/bjh.14992. Epub 2017 Nov 21.

15:An overview of the role of carfilzomib in the treatment of multiple myeloma.
Authors:Ziogas DC, Terpos E, Kastritis E, Dimopoulos MA
Institution:a Department of Clinical Therapeutics , Alexandra General Hospital, National and Kapodistrian University of Athens, School of Medicine , Athens , Greece.
Journal:Expert Opin Pharmacother. 2017 Dec;18(17):1883-1897. doi: 10.1080/14656566.2017.1404575. Epub 2017 Nov 20.

16:Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Authors:Zannetti BA, Tacchetti P, Pantani L, Gamberi B, Tosi P, Rocchi S, Cellini C, Ronconi S, Pezzi A, Mancuso K, Rizzello I, Caratozzolo I, Martello M, Dozza L, Cavo M, Zamagni E
Institution:"Seragnoli" Institute of Hematology, Sant'Orsola-Malpighi University Hospital, Bologna, Italy. Bologna, Italy. Bologna, Italy. Italy. Bologna, Italy. Cura dei Tumori" Hospital, Meldola, Italy. Bologna, Italy. Bologna, Italy. Bologna, Italy. Bologna, Italy. Bologna, Italy. Bologna, Italy.
Journal:Ann Hematol. 2017 Dec;96(12):2071-2078. doi: 10.1007/s00277-017-3140-5. Epub 2017 Oct 24.

17:Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
Authors:Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C
Institution:Mayo Clinic, Rochester, MN.
Journal:Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.

18:Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Authors:Einsele H, Engelhardt M, Tapprich C, Muller J, Liebisch P, Langer C, Kropff M, Mugge LO, Jung W, Wolf HH, Metzner B, Hart C, Gramatzki M, Hertenstein B, Pfreundschuh M, Rosler W, Fischer T, Maschmeyer G, Kanz L, Hess G, Jager E, Bentz M, Durk HA, Salwender H, Hebart H, Straka C, Knop S
Institution:University Hospital Wurzburg, Wurzburg, Germany. Germany.
Journal:Br J Haematol. 2017 Nov;179(4):586-597. doi: 10.1111/bjh.14920. Epub 2017 Sep 29.

19:Heart and Lung Complications: Assessment and Prevention of Venous Thromboembolism and Cardiovascular Disease in Patients With Multiple Myeloma.
Authors:Noonan K, Rome S, Faiman B, Verina D
Institution:Dana-Farber Cancer Institute.
Journal:Clin J Oncol Nurs. 2017 Oct 1;21(5 Suppl):37-46. doi: 10.1188/17.CJON.S5.37-46.

20:Advances in immunotherapy in multiple myeloma.
Authors:Boussi L, Niesvizky R
Institution:Division of Hematology and Medical Oncology, Multiple Myeloma Center, New York City, New York, USA.
Journal:Curr Opin Oncol. 2017 Nov;29(6):460-466. doi: 10.1097/CCO.0000000000000407.

21:Adoptive cell therapy in multiple Myeloma.
Authors:Vallet S, Pecherstorfer M, Podar K
Institution:a Department of Internal Medicine , Karl Landsteiner University of Health Sciences, University Hospital , Krems an der Donau , Austria.
Journal:Expert Opin Biol Ther. 2017 Dec;17(12):1511-1522. doi: 10.1080/14712598.2017.1375095. Epub 2017 Sep 6.

22:Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
Authors:Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, Ross JA, Maciag PC, Verdugo M, Harrison SJ
Institution:Centre Hospitalier Universitaire de Nantes, University Hospital Hotel-Dieu, Nantes, France. University of Melbourne, Melbourne, VIC, Australia. France. Nantes, France. VIC, Australia.
Journal:Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.

23:Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Authors:Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P
Institution:School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece. Electronic address: USA. Science Institute, Singapore; National University of Singapore, Singapore. Pujol, Barcelona, Spain. Ostrava, Czech Republic.
Journal:Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23.

24:Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).
Authors:Beck J, Schwarzer A, Glaser D, Mugge LO, Uhlig J, Heyn S, Kragl B, Mohren M, Hoffmann FA, Lange T, Schliwa T, Zehrfeld T, Becker C, Kreibich U, Winkelmann C, Edelmann T, Andrea M, Bill M, Jentzsch M, Schwind S, Niederwieser D, Ponisch W
Institution:Department of Haematology and Oncology, University of Leipzig, Johannisallee 32A, 04103, Leipzig, Germany. Germany. 04103, Leipzig, Germany. 04103, Leipzig, Germany. Germany. Germany. 04103, Leipzig, Germany. 04103, Leipzig, Germany. 04103, Leipzig, Germany. 04103, Leipzig, Germany. 04103, Leipzig, Germany.
Journal:J Cancer Res Clin Oncol. 2017 Dec;143(12):2545-2553. doi: 10.1007/s00432-017-2504-5. Epub 2017 Aug 21.

25:A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
Authors:Shah JJ, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Hilder BW, Rush SA, Walker DH, Tunquist BJ, Litwiler KS, Ptaszynski M, Orlowski RZ, Lonial S
Institution:Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Journal:Cancer. 2017 Dec 1;123(23):4617-4630. doi: 10.1002/cncr.30892. Epub 2017 Aug 17.

26:Systemic virotherapy for multiple myeloma.
Authors:Oliva S, Gambella M, Boccadoro M, Bringhen S
Institution:a Myeloma Unit, Division of Hematology , University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino , Torino , Italy.
Journal:Expert Opin Biol Ther. 2017 Nov;17(11):1375-1387. doi: 10.1080/14712598.2017.1364359. Epub 2017 Aug 10.

27:Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
Authors:McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M
Institution:Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hotel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ.
Journal:J Clin Oncol. 2017 Oct 10;35(29):3279-3289. doi: 10.1200/JCO.2017.72.6679. Epub 2017 Jul 25.

28:Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Authors:Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, Efebera YA, Vesole DH, Nooka AK, Rosenblatt J, Doss D, Zaki MH, Bensmaine A, Herring J, Li Y, Watkins L, Chen MS, Anderson KC
Institution:Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.; Massachusetts General Hospital, Boston, MA, USA.; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.
Journal:Leukemia. 2017 Dec;31(12):2695-2701. doi: 10.1038/leu.2017.173. Epub 2017 Jun 2.

29:Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.
Authors:Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM
Institution:Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.; Division of Hematology, Karolinska Institutet, Karolinska University Hospital at Huddinge, Stockholm, Sweden.; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.; Department Med. V, University Hospital Heidelberg, Heidelberg, Germany.
Journal:Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.

30:Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Authors:Moreau P, de Wit E
Institution:Department of Haematology, University Hospital Hotel-Dieu, Nantes, France.
Journal:Br J Haematol. 2017 Oct;179(2):198-218. doi: 10.1111/bjh.14780. Epub 2017 May 30.

31:Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).
Authors:Tessenow H, Holzvogt M, Holzvogt B, Andrea M, Heyn S, Schliwa T, Schwarz M, Zehrfeld T, Becker C, Pfrepper C, Franke GN, Krahl R, Jentzsch M, Leiblein S, Schwind S, Bill M, Vucinic V, Lange T, Niederwieser D, Ponisch W
Institution:University Hospital Leipzig, Leipzig, Germany.
Journal:J Cancer Res Clin Oncol. 2017 Oct;143(10):2049-2058. doi: 10.1007/s00432-017-2439-x. Epub 2017 May 22.

32:FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
Authors:Gormley NJ, Ko CW, Deisseroth A, Nie L, Kaminskas E, Kormanik N, Goldberg KB, Farrell AT, Pazdur R
Institution:Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, Maryland.; Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Journal:Clin Cancer Res. 2017 Nov 15;23(22):6759-6763. doi: 10.1158/1078-0432.CCR-16-2870. Epub 2017 Mar 1.

33:Current treatment options of T cell-associated immunotherapy in multiple myeloma.
Authors:Liu H, Pan Y, Meng S, Zhang W, Zhou F
Institution:Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, 710004, China. University, Wuxi, 214062, Jiangsu, China. Xi'an Jiaotong University, Xi'an, 710004, China. Xi'an Jiaotong University, Xi'an, 710004, China. Xi'an Jiaotong University, Xi'an, 710004, China. Donghu Road, Wuchang District, Wuhan, 430071, Hubei, China.
Journal:Clin Exp Med. 2017 Nov;17(4):431-439. doi: 10.1007/s10238-017-0450-9. Epub 2017 Jan 24.

For a FREE PREVIEW of the Medifocus Guidebook on Multiple Myeloma click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Multiple Myeloma click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Multiple Myeloma...
at a Special 20% Discount

Medifocus Guidebook on Multiple Myeloma

Updated: July 4, 2018
203 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Multiple Myeloma is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: September 18, 2018

What Our Customers Are Saying...

"The information in your MediFocus Guidebook on Multiple Myeloma was extremely useful. Thank you for providing this service."
Milwaukee, Wisconsin

"I purchased the MediFocus Guidebook on Multiple Myeloma for my mother and it was a great help because it helped us to understand more about the disease, the causes, and the treatment options. Although there is no cure, it has helped us cope with the situation and helped us figure out how we can live with the disease."
New York, New York

"My oncologist borrowed my copy of the MediFocus Guidebook on Multiple Myeloma and found it very useful in his work. He intends to contact your office."
Miami Beach, Florida

Medifocus Digest Alert is published by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2018 Medifocus, Inc. All rights reserved.